Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination of CXD and Restrictive Ketogenic Diet in Treating MASLD
NCT07639866Phase 2Not yet recruiting
- Sponsor
- Shanghai Municipal Hospital of Traditional Chinese Medicine
- Start
- Jul 2026
- Primary completion
- Dec 2026
01
Overview
Phase 2, randomised, single-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) (3 arms), sponsored by Shanghai Municipal Hospital of Traditional Chinese Medicine. Primary endpoint: Controlled Attenuation Parameter at 8 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT07639866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07639866.